Immuneering Corporation (IMRX)
 NASDAQ: IMRX · Real-Time Price · USD
 6.87
 +0.46 (7.18%)
  At close: Oct 31, 2025, 4:00 PM EDT
6.93
 +0.06 (0.87%)
  After-hours: Oct 31, 2025, 7:15 PM EDT
Company Description
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients.
Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors.
Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Immuneering Corporation
 | Country | United States | 
| Founded | 2008 | 
| IPO Date | Jul 30, 2021 | 
| Industry | Biotechnology | 
| Sector | Healthcare | 
| Employees | 66 | 
| CEO | Benjamin Zeskind | 
Contact Details
| Address: 245 Main Street, Second Floor Cambridge, Massachusetts 02142 United States | |
| Phone | 617 500 8080 | 
| Website | immuneering.com | 
Stock Details
| Ticker Symbol | IMRX | 
| Exchange | NASDAQ | 
| Stock Type | Common Stock | 
| Share Class | Class A Shares | 
| Fiscal Year | January - December | 
| Reporting Currency | USD | 
| IPO Price | $15.00 | 
| CIK Code | 0001790340 | 
| CUSIP Number | 45254E107 | 
| ISIN Number | US45254E1073 | 
| SIC Code | 2834 | 
Key Executives
| Name | Position | 
|---|---|
| Dr. Benjamin J. Zeskind M.B.A., Ph.D. | Co-Founder, President, Chief Executive Officer and Director | 
| Robert J. Carpenter M.B.A., M.S. | Co-Founder and Chair Emeritus | 
| Dr. Brett M. Hall Ph.D. | Chief Scientific Officer | 
| Michael D. Bookman J.D. | Chief Legal Officer and Secretary | 
| Mallory Morales CPA | Principal Financial and Accounting Officer, Chief Accounting Officer and Treasurer | 
| Paula George CPA | Director of Accounting and Operations and Assistant Corporate Controller | 
| Leah R. Neufeld | Chief People Officer | 
| Dr. Peter King Ph.D. | Head of Discovery and Vice President | 
| Dr. Praveen Nair Ph.D. | Head of Translational Pharmacology and Vice President | 
| Harold E. Brakewood | Chief Business Officer | 
Latest SEC Filings
| Date | Type | Title | 
|---|---|---|
| Oct 21, 2025 | SCHEDULE 13G | Filing | 
| Oct 7, 2025 | SCHEDULE 13G | Filing | 
| Oct 3, 2025 | SCHEDULE 13G | Filing | 
| Sep 25, 2025 | 424B5 | Filing | 
| Sep 25, 2025 | 8-K | Current Report | 
| Sep 25, 2025 | FWP | Free Writing Prospectus | 
| Sep 24, 2025 | FWP | Free Writing Prospectus | 
| Sep 24, 2025 | 424B5 | Filing | 
| Sep 24, 2025 | 8-K | Current Report | 
| Sep 23, 2025 | 144 | Filing |